Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Int J Mol Sci ; 23(4)2022 Feb 15.
Article in English | MEDLINE | ID: mdl-35216261

ABSTRACT

Un-complexed polynuclear ferric oxyhydroxide cannot be administered safely or effectively to patients. When polynuclear iron cores are formed with carbohydrates of various structures, stable complexes with surface carbohydrates driven by multiple interacting sites and forces are formed. These complexes deliver iron in a usable form to the body while avoiding the serious adverse effects of un-complexed forms of iron, such as polynuclear ferric oxyhydroxide. The rate and extent of plasma clearance and tissue biodistribution is variable among the commercially available iron-carbohydrate complexes and is driven principally by the surface characteristics of the complexes which dictate macrophage opsonization. The surface chemistry differences between the iron-carbohydrate complexes results in significant differences in in vivo pharmacokinetic and pharmacodynamic profiles as well as adverse event profiles, demonstrating that the entire iron-carbohydrate complex furnishes the pharmacologic action for these complex products. Currently available physicochemical characterization methods have limitations in biorelevant matrices resulting in challenges in defining critical quality attributes for surface characteristics for this class of complex nanomedicines.


Subject(s)
Carbohydrates/pharmacology , Carbohydrates/pharmacokinetics , Iron Compounds/pharmacology , Iron Compounds/pharmacokinetics , Iron/pharmacology , Iron/pharmacokinetics , Nanoparticles/metabolism , Administration, Intravenous/methods , Animals , Ferric Compounds/metabolism , Humans
2.
J Nutr ; 151(Suppl 1): 3S-14S, 2021 02 15.
Article in English | MEDLINE | ID: mdl-33582781

ABSTRACT

This introductory article provides an in-depth technical background for iron fortification, and thus introduces a series of articles in this supplement designed to present the current evidence on the fortification of salt with both iodine and iron, that is, double-fortified salt (DFS). This article reviews our current knowledge of the causes and consequences of iron deficiency and anemia and then, with the aim of assisting the comparison between DFS and other common iron-fortified staple foods, discusses the factors influencing the efficacy of iron-fortified foods. This includes the dietary and physiological factors influencing iron absorption; the choice of an iron compound and the fortification technology that will ensure the necessary iron absorption with no sensory changes; encapsulation of iron fortification compounds to prevent unacceptable sensory changes; the addition of iron absorption enhancers; the estimation of the iron fortification level for each vehicle based on iron requirements and consumption patterns; and the iron status biomarkers that are needed to demonstrate improved iron status in populations regularly consuming the iron-fortified food. The supplement is designed to provide a summary of evidence to date that can help advise policy makers considering DFS as an intervention to address the difficult public health issue of iron deficiency anemia, while at the same time using DFS to target iodine deficiency.


Subject(s)
Absorption, Physiological , Food Technology , Food, Fortified , Iodine , Iron, Dietary/administration & dosage , Iron, Dietary/pharmacokinetics , Sodium Chloride, Dietary , Anemia, Iron-Deficiency/prevention & control , Biological Availability , Biomarkers , Humans , Iron Compounds/administration & dosage , Iron Compounds/pharmacokinetics , Nutritional Status
3.
Article in English | MEDLINE | ID: mdl-29869925

ABSTRACT

A novel aluminum/olivine composite (AOC) was prepared by wet impregnation followed by calcination and was introduced as an efficient adsorbent for defluoridation. The adsorption of fluoride was modeled with one-, two- and three-parameter isotherm equations by non-linear regression to demonstrate the adsorption equilibrium. The FI was the best-fitted model among the two-parameter isotherms with a R2 value of 0.995. The three-parameter models were found to have better performance with low values of the error functions and high F values. The neural-network-based model was applied for the first time in the isotherm study. The optimized model was framed with eight neurons in hidden layer with a mean square of error of 0.0481 and correlation coefficient greater than 0.999. The neural-based model has the better predictability with a higher F value of 9484 and R2 value of 0.998 compared to regression models, exhibiting the F value and the R2 in the range of 86-3572 and 0.835-0.995, respectively. The material characterization established the formation of the aluminum oxide, silicate, etc. onto the olivine which is conducive of the removal of fluoride by the formation of aluminum fluoride compounds, such as AlF3 in the spent material after defluoridation.


Subject(s)
Fluorides/pharmacokinetics , Iron Compounds/pharmacokinetics , Magnesium Compounds/pharmacokinetics , Neural Networks, Computer , Silicates/pharmacokinetics , Water Purification , Absorption, Physicochemical , Aluminum/chemistry , Aluminum/pharmacokinetics , Aluminum Oxide/chemistry , Chemical Phenomena , Fluorides/chemistry , Iron Compounds/chemistry , Kinetics , Least-Squares Analysis , Magnesium Compounds/chemistry , Silicates/chemistry , Temperature , Water Purification/instrumentation , Water Purification/methods
4.
Regul Toxicol Pharmacol ; 97: 17-23, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29857115

ABSTRACT

Intravenous (IV) iron formulations are complex colloidal suspensions of iron oxide nanoparticles. Small changes in formulation can allow more labile iron to be released after injection causing toxicity. Thus, bioequivalence (BE) evaluation of generic IV iron formulations remains challenging. We evaluated labile iron release in vitro and in vivo using a high performance liquid chromatography chelatable iron assay to develop a relational model to support BE. In vitro labile iron release and in vivo labile iron pharmacokinetics were evaluated for Venofer®, Ferrlecit®, generic sodium ferric gluconate complex, InFeD®, Feraheme® and a pre-clinical formulation GE121333. Labile iron release profiles were studied in vitro in 150 mM saline and a biorelevant matrix (rat serum) at 0.952 mgFe/mL. In vivo plasma labile iron concentration-time profiles (t0-240 min) were studied in rats after a 40 mgFe/kg IV dose. In vitro labile iron release in saline was significantly higher compared to rat serum, especially with InFeD®. An in vitro release constant (iKr) was calculated which correlated well with maximal plasma concentrations in the in vivo rat PK model (R2 = 0.711). These data suggest an in vitro to in vivo correlation model of labile iron release kinetics could be applied to BE. Other generic IV iron formulations need to be studied to validate this model.


Subject(s)
Chelating Agents/chemistry , Deferoxamine/chemistry , Iron Compounds/blood , Nanoparticles/chemistry , Administration, Intravenous , Animals , Iron Compounds/administration & dosage , Iron Compounds/pharmacokinetics , Kinetics , Male , Nanoparticles/administration & dosage , Rats , Rats, Sprague-Dawley
5.
Nanomedicine (Lond) ; 11(7): 783-96, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26979124

ABSTRACT

BACKGROUND: While carbon-encapsulated iron carbide nanoparticles exhibit strong magnetic properties appealing for biomedical applications, potential side effects of such materials remain comparatively poorly understood. Here, we assess the effects of iron-based nanoparticles in an in vivo long-term study in mice with observation windows between 1 week and 1 year. MATERIALS & METHODS: Functionalized (PEG or IgG) carbon-encapsulated platinum-spiked iron carbide nanoparticles were injected intravenously in mice (single or repeated dose administration). RESULTS: One week after administration, magnetic nanoparticles were predominantly localized in organs of the reticuloendothelial system, particularly the lung and liver. After 1 year, particles were still present in these organs, however, without any evident tissue alterations, such as inflammation, fibrosis, necrosis or carcinogenesis. Importantly, reticuloendothelial system organs presented with normal function. CONCLUSION: This long-term exposure study shows high in vivo compatibility of intravenously applied carbon-encapsulated iron nanoparticles suggesting continuing investigations on such materials for biomedical applications.


Subject(s)
Carbon Compounds, Inorganic/adverse effects , Carbon/adverse effects , Coated Materials, Biocompatible/adverse effects , Drug Carriers/adverse effects , Iron Compounds/adverse effects , Nanoparticles/adverse effects , Animals , Carbon/administration & dosage , Carbon/chemistry , Carbon/pharmacokinetics , Carbon Compounds, Inorganic/administration & dosage , Carbon Compounds, Inorganic/chemistry , Carbon Compounds, Inorganic/pharmacokinetics , Coated Materials, Biocompatible/administration & dosage , Coated Materials, Biocompatible/chemistry , Drug Carriers/administration & dosage , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Female , Iron Compounds/administration & dosage , Iron Compounds/chemistry , Iron Compounds/pharmacokinetics , Liver/drug effects , Liver/metabolism , Liver/ultrastructure , Lung/drug effects , Lung/metabolism , Lung/ultrastructure , Magnets/adverse effects , Magnets/chemistry , Male , Mice , Mice, Inbred C57BL , Nanoparticles/administration & dosage , Nanoparticles/analysis , Nanoparticles/chemistry
6.
Theranostics ; 5(11): 1225-32, 2015.
Article in English | MEDLINE | ID: mdl-26379788

ABSTRACT

Iron oxide nanoparticles have been extensively used as T2 contrast agents for liver-specific magnetic resonance imaging (MRI). The applications, however, have been limited by their mediocre magnetism and r2 relaxivity. Recent studies show that Fe5C2 nanoparticles can be prepared by high temperature thermal decomposition. The resulting nanoparticles possess strong and air stable magnetism, suggesting their potential as a novel type of T2 contrast agent. To this end, we improve the synthetic and surface modification methods of Fe5C2 nanoparticles, and investigated the impact of size and coating on their performances for liver MRI. Specifically, we prepared 5, 14, and 22 nm Fe5C2 nanoparticles and engineered their surface by: 1) ligand addition with phospholipids, 2) ligand exchange with zwitterion-dopamine-sulfonate (ZDS), and 3) protein adsorption with casein. It was found that the size and surface coating have varied levels of impact on the particles' hydrodynamic size, viability, uptake by macrophages, and r2 relaxivity. Interestingly, while phospholipid- and ZDS-coated Fe5C2 nanoparticles showed comparable r2, the casein coating led to an r2 enhancement by more than 2 fold. In particular, casein coated 22 nm Fe5C2 nanoparticle show a striking r2 of 973 mM(-1)s(-1), which is one of the highest among all of the T2 contrast agents reported to date. Small animal studies confirmed the advantage of Fe5C2 nanoparticles over iron oxide nanoparticles in inducing hypointensities on T2-weighted MR images, and the particles caused little toxicity to the host. The improvements are important for transforming Fe5C2 nanoparticles into a new class of MRI contrast agents. The observations also shed light on protein-based surface modification as a means to modulate contrast ability of magnetic nanoparticles.


Subject(s)
Carbon Compounds, Inorganic/administration & dosage , Coated Materials, Biocompatible/administration & dosage , Contrast Media/administration & dosage , Iron Compounds/administration & dosage , Liver/pathology , Magnetic Resonance Imaging/methods , Magnetics , Nanoparticles/administration & dosage , Animals , Carbon Compounds, Inorganic/adverse effects , Carbon Compounds, Inorganic/pharmacokinetics , Caseins/metabolism , Coated Materials, Biocompatible/adverse effects , Coated Materials, Biocompatible/pharmacokinetics , Contrast Media/adverse effects , Contrast Media/pharmacokinetics , Iron Compounds/adverse effects , Iron Compounds/pharmacokinetics , Models, Animal , Nanoparticles/adverse effects
7.
Environ Sci Technol ; 48(22): 13468-77, 2014 Nov 18.
Article in English | MEDLINE | ID: mdl-25358072

ABSTRACT

Floodplain soils are frequently contaminated with metal(loid)s due to present or historic mining, but data on the bioaccessibility (BA) of contaminants in these periodically flooded soils are scarce. Therefore, we studied the speciation of As and Fe in eight As-contaminated circumneutral floodplain soils (≤ 21600 mg As/kg) and their size fractions using X-ray absorption spectroscopy (XAS) and examined the BA of As in the solids by in-vitro gastrointestinal (IVG) extractions. Arsenopyrite and As(V)-adsorbed ferrihydrite were identified by XAS as the predominant As species. The latter was the major source for bioaccessible As, which accounted for 5-35% of the total As. The amount of bioaccessible As increased with decreasing particle size and was controlled by the slow dissolution kinetics of ferrihydrite in the gastric environment (pH 1.8). The relative BA of As (% of total) decreased with decreasing particle size only in a highly As-contaminated soil--which supported by Fe XAS--suggests the formation of As-rich hydrous ferric oxides in the gastric extracts. Multiple linear regression analyses identified Al, total As, C(org), and P as main predictors for the absolute BA of As (adjusted R(2) ≤ 0.977). Health risk assessments for residential adults showed that (i) nearly half of the bulk soils may cause adverse health effects and (ii) particles <5 µm pose the highest absolute health threat upon incidental soil ingestion. Owing to their low abundance, however, health risks were primarily associated with particles in the 5-50 and 100-200 µm size ranges. These particles are easily mobilized from riverbanks during flooding events and dispersed within the floodplain or transported downstream.


Subject(s)
Arsenic/pharmacokinetics , Mining , Soil Pollutants/pharmacokinetics , Soil/chemistry , Arsenicals/pharmacokinetics , Environmental Pollution/analysis , Ferric Compounds/pharmacokinetics , Iron Compounds/pharmacokinetics , Minerals/pharmacokinetics , Rivers , Sulfides/pharmacokinetics , X-Ray Absorption Spectroscopy
8.
Contrast Media Mol Imaging ; 7(1): 35-44, 2012.
Article in English | MEDLINE | ID: mdl-22344878

ABSTRACT

Islets can be visualized on MRI by labeling with superparamagnetic contrast agent during the transplantation procedure. However, whether the signal intensity reflects the cell number and cellular viability has not been determined. We used a self-synthesized novel superparamagnetic contrast agent -polyvinylpyrrolidone-coated superparamagnetic iron oxide nanoparticles (PVP-SPIO) - to label ß-TC-6 cells (a mouse insulinoma cell line) or primary islets with commercial Feridex as a control. The labeling efficiency of two agents was compared by Prussian blue staining, intracellular iron content determination and MR scanning. Cells were exposed to hypoxia, high-glucose or exogenous H2O2 stimulation before/after PVP-SPIO labeling. Normal and injured cells were also transplanted into renal subcapsule. A clinically used 3.0 T MR scan was performed in vitro and 24 h post-transplantation to investigate the correlation between cellular viability and signal. Our PVP-SPIO displayed superior biocompatibility and magnetic properties. All of the cells could be labeled at 100 µg/ml iron concentration after 24 h incubation. At 100 µg/ml iron concentration, 1 × 105 ß cells labeled with PVP-SPIO could already be visualized in vitro by MRI, less than the detection threshold of Feridex. There existed a linear correlation between the number of labeled cells and R2 value on the T2 -weighted images. The signal intensity and the intracellular iron content declined along with the decreased viability of labeled cells. There was also a significant difference in signal intensity between injured and normal labeled cells after transplantation. From these results, we concluded that PVP-SPIO possessed superior cell labeling efficiency, and ß cells could be labeled without compromising viability and function. The signal intensity on MRI might be a useful predictor to evaluate the number and the viability of PVP-SPIO-labeled cells.


Subject(s)
Cell Tracking/methods , Contrast Media/analysis , Graft Survival , Iron Compounds/analysis , Islets of Langerhans Transplantation , Magnetic Resonance Imaging/methods , Magnetite Nanoparticles/analysis , Oxides/analysis , Povidone/analysis , Animals , Cell Hypoxia , Cell Line, Tumor , Cell Survival , Contrast Media/pharmacokinetics , Dextrans/analysis , Dextrans/pharmacokinetics , Ferrocyanides , Glucose/pharmacology , Hydrogen Peroxide/pharmacology , Insulinoma/pathology , Iron Compounds/pharmacokinetics , Islets of Langerhans/drug effects , Islets of Langerhans/metabolism , Mice , Mice, Inbred C57BL , Oxides/pharmacokinetics , Pancreatic Neoplasms/pathology , Povidone/analogs & derivatives , Povidone/pharmacokinetics , Staining and Labeling , Subrenal Capsule Assay
9.
Contrast Media Mol Imaging ; 7(1): 51-8, 2012.
Article in English | MEDLINE | ID: mdl-22344880

ABSTRACT

The aim of this work was to investigate the MRI findings on tumor xenografts induced in nude mice by the inoculation of human pancreatic cancer cells labeled with superparamagnetic iron oxide (SPIO), and to monitor the kinetics of SPIO distribution in tumor xenografts. The labeled cancer cells were subcutaneously inoculated into 11 nude mice to induce tumor xenograft. The unlabeled cancer cells served as a control inoculated into nine nude mice. MR imaging was performed with a 1.5 T MR scanner for the tumor xenograft at the first, second and third week after the inoculation. We found that the tumor xenograft was induced in 100% nude mice on MR imaging for both groups in the first week after the inoculation. In the SPIO group, the tumors showed homogeneous hypointensity on T1 - and T2 -weighted and FIESTA images 1 week after inoculation. Two and 3 weeks after inoculation, the center of the tumors was still hypointense on all the above sequences. The tumor periphery was isointense on T1 -weighted, and hyperintense on T2 -weighted and FIESTA images. The tumors in control group were homogeneously hypointense or isointense on T1 -weighted, and hyperintense on T2 -weighted and FIESTA images in the first, second and third week after the inoculation. The size and signal-to-noise ratio of the tumor center in the SPIO group had decreased subsequent to the inoculation in all T1 - and T2 -weighted images and FIESTA. Our results showed the human pancreatic cancer cells labeled with SPIO can induce tumor xenograft in nude mice and MRI can monitor the kinetics of SPIO distribution in tumor xenografts.


Subject(s)
Carcinoma, Pancreatic Ductal/pathology , Cell Tracking/methods , Contrast Media , Imaging, Three-Dimensional/methods , Iron Compounds , Magnetic Resonance Imaging/methods , Oxides , Pancreatic Neoplasms/pathology , Animals , Cell Line, Tumor/transplantation , Corpus Striatum/pathology , Dextrans/pharmacokinetics , Humans , Image Processing, Computer-Assisted , Iron Compounds/analysis , Iron Compounds/pharmacokinetics , Magnetite Nanoparticles , Mice , Mice, Nude , Oxides/analysis , Oxides/pharmacokinetics , Tissue Distribution , Transplantation, Heterologous
10.
Ter Arkh ; 84(12): 85-7, 2012.
Article in Russian | MEDLINE | ID: mdl-23479997

ABSTRACT

AIM: To comparatively evaluate the efficiency of preventive treatment with various iron preparations on copper, manganese, and iron metabolic features in adult athletes. SUBJECTS AND METHODS: Forty adult highly qualified sambo wrestlers were examined and divided into 4 groups of 10 persons in each. Group 1 athletes took iron-containing Sorbifer Durules in combination with ascorbic acid; Group 2 received Ferro Gradumet Vitamin C; Group 3 had Hemofer and ascorbic acid; Group 4 took ascorbic acid tablets. The latter group served as a control. Blood samples (15-20 ml) to be tested were taken at the beginning and end of 2-week use of iron preparations. The daily balance of iron, copper, and manganese was estimated following 7-day intake of these preparations. RESULTS: The use of iron-containing preparations in combination with ascorbic acid was ascertained to be accompanied by an increment in the plasma concentration of iron and blood corpuscles, indicating an increased need for this biotic and its deficiency in athletes. When the dose of iron was increased in the iron preparations, there was a substantial rise in the excretion of copper, manganese in particular, through the gastrointestinal tract and kidney and a negative balance of these trace elements in the body. CONCLUSION: Dietary addition of foods containing large amounts of ferrous iron, copper, and manganese is indicated for athletes exposed to higher intensity exercises.


Subject(s)
Ascorbic Acid , Copper , Iron Compounds , Iron Metabolism Disorders/prevention & control , Iron , Manganese , Adult , Ascorbic Acid/administration & dosage , Ascorbic Acid/pharmacokinetics , Athletes , Copper/analysis , Copper/metabolism , Diet Therapy/methods , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Humans , Iron/metabolism , Iron Compounds/administration & dosage , Iron Compounds/pharmacokinetics , Iron Deficiencies , Iron Metabolism Disorders/etiology , Iron Metabolism Disorders/metabolism , Male , Manganese/analysis , Manganese/metabolism , Metabolic Clearance Rate/drug effects , Primary Prevention/methods , Spectrum Analysis/methods , Sports/physiology , Trace Elements/analysis , Trace Elements/metabolism , Vitamins/administration & dosage , Vitamins/pharmacokinetics
11.
Pak J Biol Sci ; 14(20): 945-9, 2011 Oct 15.
Article in English | MEDLINE | ID: mdl-22514896

ABSTRACT

Rat Everted Gut Sac (EGS) model was employed to study the intestinal uptake of titanium and iron. Incubation of freshly prepared rat EGS in Earle's medium pH = 7.4 containing titanium showed that the absorption of titanium as well as iron was a dose dependent process. Ascorbic acid enhanced the absorption of both metal ions, while NaF (1 mM) as an inhibitor of glycolytic energy supply, decreased their absorption. The Na+-K+ ATPase inhibitor, ouabain (1 mM) reduced intestinal absorption of Titanium. This suggests that titanium uptake is an active transport process as is iron uptake. Iron absorption was reduced approximate by 17% when titanium was presented to incubation medium EGS whereas, the absorption of titanium was decreased by 35% when iron was added to the reaction mixture.


Subject(s)
Intestinal Mucosa/metabolism , Iron Compounds/pharmacokinetics , Titanium/pharmacokinetics , Animals , Ascorbic Acid/metabolism , Biological Transport/drug effects , Biological Transport, Active/drug effects , Citric Acid/pharmacokinetics , Intestinal Absorption , Intestinal Mucosa/drug effects , Male , Ouabain/pharmacology , Rats , Rats, Wistar , Sodium Fluoride/pharmacology , Sodium-Potassium-Exchanging ATPase/antagonists & inhibitors
12.
Colloids Surf B Biointerfaces ; 80(1): 79-85, 2010 Oct 01.
Article in English | MEDLINE | ID: mdl-20620892

ABSTRACT

Equilibrium adsorption along with scanning electron microscopy (SEM), Fourier transform infrared (FTIR) and isothermal titration calorimetry (ITC) techniques were employed to investigate the adhesion of Pseudomonas putida on goethite. The adhesion isotherm revealed the high affinity of P. putida for goethite. The SEM analysis also showed a tight association between bacteria and mineral particles. Larger amounts of adhesion of bacteria on goethite were observed at pH lower than the isoelectric point (IEP) of goethite. The bacterial adhesion increased with increasing concentration of K(+). The calorimetric results demonstrated that the P. putida-goethite adhesion was an exothermic process. The adhesion enthalpy increased with increasing pH and concentrations of electrolyte. The increase of the negative enthalpy with increment of temperature indicated that the bacteria-goethite adhesion was an enthalpy-driven process. Electrostatic interactions and hydrogen bonding were considered to contribute mainly to the adhesion of bacterial adhesion on goethite. The data obtained in this study would provide valuable information for a better understanding of the mechanisms of mineral-microorganism interactions in soil and associated environments.


Subject(s)
Bacterial Adhesion/physiology , Iron Compounds/chemistry , Pseudomonas putida/physiology , Adsorption , Bacterial Adhesion/drug effects , Calorimetry/methods , Hydrogen-Ion Concentration , Iron Compounds/pharmacokinetics , Kinetics , Microscopy, Electron, Scanning , Minerals , Potassium/pharmacology , Pseudomonas putida/ultrastructure , Spectroscopy, Fourier Transform Infrared , Temperature , Thermodynamics
13.
Food Nutr Bull ; 31(1 Suppl): S7-21, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20629349

ABSTRACT

BACKGROUND: Iron fortification of wheat flour is widely used as a strategy to combat iron deficiency. OBJECTIVE: To review recent efficacy studies and update the guidelines for the iron fortification of wheat flour. METHODS: Efficacy studies with a variety of iron-fortified foods were reviewed to determine the minimum daily amounts of additional iron that have been shown to meaningfully improve iron status in children, adolescents, and women of reproductive age. Recommendations were computed by determining the fortification levels needed to provide these additional quantities of iron each day in three different wheat flour consumption patterns. Current wheat flour iron fortification programs in 78 countries were evaluated. RESULTS: When average daily consumption of low-extraction (< or = 0.8% ash) wheat flour is 150 to 300 g, it is recommended to add 20 ppm iron as NaFeEDTA, or 30 ppm as dried ferrous sulfate or ferrous fumarate. If sensory changes or cost limits the use of these compounds, electrolytic iron at 60 ppm is the second choice. Corresponding fortification levels were calculated for wheat flour intakes of < 150 g/day and > 300 g/day. Electrolytic iron is not recommended for flour intakes of < 150 g/day. Encapsulated ferrous sulfate or fumarate can be added at the same concentrations as the non-encapsulated compounds. For high-extraction wheat flour (> 0.8% ash), NaFeEDTA is the only iron compound recommended. Only nine national programs (Argentina, Chile, Egypt, Iran, Jordan, Lebanon, Syria, Turkmenistan, and Uruguay) were judged likely to have a significant positive impact on iron status if coverage is optimized. Most countries use non-recommended, low-bioavailability, atomized, reduced or hydrogen-reduced iron powders. CONCLUSION: Most current iron fortification programs are likely to be ineffective. Legislation needs updating in many countries so that flour is fortified with adequate levels of the recommended iron compounds.


Subject(s)
Flour/analysis , Food, Fortified/standards , Iron/administration & dosage , Nutrition Policy/trends , Triticum , Adolescent , Adult , Anemia, Iron-Deficiency/prevention & control , Child , Diet , Evaluation Studies as Topic , Female , Guidelines as Topic , Humans , Internationality , Iron/chemistry , Iron Compounds/administration & dosage , Iron Compounds/pharmacokinetics , Iron Deficiencies , Male , Nutritional Status , Young Adult
15.
Med Oncol ; 26(1): 105-15, 2009.
Article in English | MEDLINE | ID: mdl-18473194

ABSTRACT

UNLABELLED: Cancer-related anemia is common and multifactorial in origin. Functional iron deficiency (FID) is now recognized as a cause of iron-restricted erythropoiesis and may be one of the major reasons for lack of response to treatment with Erythropoietic Stimulating Agents (ESAs). Numerous studies have shown that intravenous (IV), but not oral, iron therapy effectively provides sufficient iron for optimal erythropoiesis in anemic patients with chronic renal disease receiving ESA therapy. The use of IV iron has also been suggested in the cancer setting. Six recent studies have tested this assumption and are summarized in this review. Four formulations of IV iron are available in Europe, with different pharmacokinetics, iron bioavailability, and risk of acute adverse drug reactions. CONCLUSION: Limited iron stores and FID are common causes of response failure during ESA treatment in cancer patients and should be diagnosed. There is now substantial scientific support for the use of IV iron supplementation to improve response and this has been acknowledged in international and national guidelines. Prospective long-term data on the safety of IV iron in this setting are still awaited. Recommendations concerning the optimal formulation, doses, and schedule of iron supplementation to ESA treatment in cancer-related anemia are provisional awaiting data from prospective, randomized trials.


Subject(s)
Anemia, Iron-Deficiency , Hematinics/administration & dosage , Iron Compounds/administration & dosage , Neoplasms/complications , Administration, Oral , Anemia, Iron-Deficiency/drug therapy , Anemia, Iron-Deficiency/etiology , Drug Administration Schedule , Erythropoiesis/drug effects , Ferric Compounds/administration & dosage , Ferric Compounds/adverse effects , Ferric Compounds/pharmacokinetics , Ferric Oxide, Saccharated , Ferrous Compounds/administration & dosage , Ferrous Compounds/adverse effects , Ferrous Compounds/pharmacokinetics , Glucaric Acid , Hematinics/adverse effects , Hematinics/pharmacokinetics , Humans , Infusions, Intravenous , Iron Compounds/adverse effects , Iron Compounds/pharmacokinetics , Iron, Dietary/administration & dosage , Iron, Dietary/adverse effects , Iron, Dietary/pharmacokinetics , Iron-Dextran Complex/administration & dosage , Iron-Dextran Complex/adverse effects , Iron-Dextran Complex/pharmacokinetics , Maltose/administration & dosage , Maltose/adverse effects , Maltose/analogs & derivatives , Maltose/pharmacokinetics , Randomized Controlled Trials as Topic
16.
Am J Clin Nutr ; 89(2): 533-8, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19073788

ABSTRACT

BACKGROUND: Hepcidin is a key regulator of iron homeostasis, but to date no studies have examined the effect of hepcidin on iron absorption in humans. OBJECTIVE: Our objective was to assess relations between both serum hepcidin and serum prohepcidin with nonheme-iron absorption in the presence and absence of food with the use of dual stable-iron-isotope techniques. DESIGN: The study group included 18 healthy nonpregnant women. Women received in random order a supplemental iron source (7.6 mg FeSO4 providing 0.9 mg 58Fe as FeSO4) and 6.8 mg 57Fe ferrous sulfate tracer administered with a nonheme food source [orange-fleshed sweet potato (OFSP): 1.4 mg native Fe]. Iron absorption was determined by analyzing blood samples taken 14 d after dosing with the use of magnetic sector thermal ionization mass spectrometry. Serum hepcidin was assessed by a new competitive serum enzyme-linked immunosorbent assay (ELISA) specific for the refolded, mature 25-amino acid form, and serum prohepcidin was assessed by an ELISA specific for amino acids 28-47 of the hepcidin prohormone. RESULTS: In these women, iron absorption averaged 14.71 +/- 10.7% from the supplemental iron compared with 3.63 +/- 6.5% from the OFSP. Absorption of nonheme iron assessed in the presence (P = 0.038) and absence (P = 0.0296) of food was significantly associated with serum hepcidin but was not significantly related to serum prohepcidin. CONCLUSION: Serum hepcidin, but not prohepcidin, was inversely associated with iron absorption from supplemental and food-based nonheme-iron sources in iron-replete healthy women.


Subject(s)
Antimicrobial Cationic Peptides/blood , Dietary Supplements , Intestinal Absorption/drug effects , Iron, Dietary/pharmacokinetics , Protein Precursors/blood , Adolescent , Adult , Antimicrobial Cationic Peptides/pharmacology , Biological Availability , Enzyme-Linked Immunosorbent Assay , Female , Ferritins/blood , Hemoglobins/analysis , Hepcidins , Humans , Ipomoea batatas/chemistry , Iron Compounds/blood , Iron Compounds/metabolism , Iron Compounds/pharmacokinetics , Iron Isotopes , Iron, Dietary/blood , Iron, Dietary/metabolism , Mass Spectrometry , Nutritional Status , Premenopause , Protein Precursors/pharmacology , Young Adult
17.
Toxicol Appl Pharmacol ; 229(3): 273-80, 2008 Jun 15.
Article in English | MEDLINE | ID: mdl-18384829

ABSTRACT

The relation between haem biosynthesis and intestinal iron absorption is not well understood, we therefore investigated the effect of compounds that alter haem metabolism on duodenal iron absorption. CD1 mice were treated with either an inhibitor (succinyl acetone (SA)) or stimulator (2-allyl-2-isopropylacetamide (AIA)) of haem biosynthesis. 5-Aminolaevulinic acid (ALA) dehydratase and urinary ALA and porphobilinogen (PBG) levels, were determined. Intestinal iron absorption was assayed with in vivo and in vitro techniques. Liver hepcidin (Hamp1) and duodenal iron transporter mRNA levels were measured using RT-PCR. AIA caused increased hepatic ALA synthase (1.6-fold) and ALA dehydratase (1.4-fold, both p<0.005) activities and increased urinary ALA and PBG excretion (2.1- and 1.4-fold, p<0.005, p<0.05, respectively). In vivo intestinal iron absorption was reduced to 49% of control (p<0.005). Mice treated with SA showed decreased urinary ALA and PBG levels (75 and 55% control, both p<0.005) and reductions in both ALA synthase and ALA dehydratase activities (77 and 56% control, p<0.05, p<0.005, respectively) in the liver. Liver and duodenal haem and cytochrome oxidase levels were not significantly decreased. Iron absorption was enhanced (1.26-fold, p<0.05) and hepatic Hamp1 mRNA was reduced (53% of control, p<0.05). In vitro duodenal iron uptake after mice were injected with SA also demonstrated an increase in Fe(III) reduction and uptake (1.27- and 1.41-fold, p<0.01 respectively). Simultaneous injections of SA and ALA blocked the enhancing effect on iron absorption seen with SA alone. We conclude that alterations in haem biosynthesis can influence iron absorption and in particular, the intermediate ALA seems to be an inhibitor of iron absorption.


Subject(s)
Aminolevulinic Acid/metabolism , Heme/biosynthesis , Intestinal Absorption , Iron Compounds/pharmacokinetics , Allylisopropylacetamide/pharmacology , Aminolevulinic Acid/urine , Animals , Antimicrobial Cationic Peptides/metabolism , Duodenum/metabolism , Enzyme Inhibitors/pharmacology , Hepcidins , Heptanoates/pharmacology , Male , Mice , Porphobilinogen/metabolism , Porphobilinogen Synthase/metabolism , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction
18.
J Control Release ; 121(3): 181-9, 2007 Aug 28.
Article in English | MEDLINE | ID: mdl-17644206

ABSTRACT

Magnetic sponge-like hydrogels (ferrosponges) were fabricated by using an in-situ synthesis of magnetic nanoparticles (MNPs) in the presence of various concentrations of gelatin. The resulting ferrosponges show an interconnected nanopore structure which serves as a reservoir to accommodate therapeutic drugs and the nanoporous networks demonstrate magnetic sensitive behavior under the application of magnetic field. The ferrosponges showed high swelling ratios, together with excellent elasticity and hydrophilicity, allow them to response rapidly to an external magnetic stimulation for fast and repeatable swelling-deswelling (or expansion-contractile) operations. The ferrosponges with lower gelatin concentration exhibited good performance on magnetification. Furthermore, drug release from the ferrosponges is relatively magnetic-sensitive and is dominated by its magnetism and associated interaction between the magnetic nanoparticle and the gelatin matrix under an external magnetic field. Higher MNPs concentration in the ferrosponges exhibited higher degree of magnetic sensitive which is due to stronger interparticle forces. By taking these peculiar magnetic sensitive behaviors of the ferrosponges, a novel drug delivery system can be designed for medical uses.


Subject(s)
Drug Delivery Systems/methods , Gelatin Sponge, Absorbable/administration & dosage , Iron Compounds/administration & dosage , Nanoparticles/administration & dosage , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/pharmacokinetics , Gelatin Sponge, Absorbable/pharmacokinetics , Hydrogels/administration & dosage , Hydrogels/pharmacokinetics , Iron Compounds/pharmacokinetics , Magnetics
19.
Bioresour Technol ; 98(8): 1622-8, 2007 May.
Article in English | MEDLINE | ID: mdl-16935492

ABSTRACT

Yeast biomass enriched with iron could represent a new and safer solution for prevention from anaemia development. Such an iron source is less toxic and has better absorbability in organisms. The purpose of our research was the determination of the most suitable iron source in the cultivation medium for the yeast Saccharomyces cerevisiae, regarding good growth and iron accumulation in cells. Iron(III) citrate, iron(III) chloride, iron(III) nitrate and Fe-EDTA complex were used. The uptake of the chosen iron compound, Fe(III) citrate, by the yeasts Candida intermedia and Kluyveromyces marxianus was also investigated. Different growth behaviour of the three yeast strains in the presence of Fe(III) citrate was observed. The highest amounts of accumulated iron in S. cerevisiae, C. intermedia and K. marxianus biomass were about 13, 20 and 34mgFeg(-1)dry wt., respectively. To optimise the accumulation of iron in K. marxianus and to characterise iron enriched yeast biomass, further experiments are needed.


Subject(s)
Culture Media/metabolism , Iron Compounds/metabolism , Yeasts/growth & development , Yeasts/metabolism , Animal Feed , Biomass , Dietary Supplements , Iron Compounds/pharmacokinetics , Time Factors
20.
Toxicol Sci ; 95(1): 281-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17005634

ABSTRACT

A number of studies have found that gastrointestinal absorption of arsenic from soil is limited, indicating that a relative oral bioavailability (RBA) adjustment is warranted when calculating risks from exposure to arsenic-contaminated soil. However, few studies of arsenic bioavailability from soil have been conducted in animal models with phylogenetic similarity to humans, such as nonhuman primates. We report here the results of a study in which the RBA of arsenic in soil from a variety of types of contaminated sites was measured in male cynomolgus monkeys. A single oral dose of each contaminated soil was administered to five adult male cynomolgus monkeys by gavage, and the extent of oral absorption was evaluated through measurement of arsenic recovery in urine and feces. Urinary recovery of arsenic following doses of contaminated soil was compared with urinary recovery following oral administration of sodium arsenate in water in order to determine the RBA of each soil. RBA of arsenic in 14 soil samples from 12 different sites ranged from 0.05 to 0.31 (5-31%), with most RBA values in the 0.1-0.2 (10-20%) range. The RBA values were found to be inversely related to the amount of arsenic present with iron sulfate. No other significant correlations were observed between RBA and arsenic mineralogic phases in the test soils. The lack of clear relationships between arsenic mineralogy and RBA measured in vivo suggests that gastrointestinal absorption of arsenic from soil may be more complex than originally thought, and subject to factors other than simple dissolution behavior.


Subject(s)
Arsenicals/pharmacokinetics , Intestinal Absorption , Soil Pollutants/pharmacokinetics , Animals , Arsenates/pharmacokinetics , Arsenates/urine , Arsenicals/analysis , Arsenicals/urine , Biological Availability , Feces/chemistry , Ferrous Compounds/analysis , Iron Compounds/pharmacokinetics , Iron Compounds/urine , Linear Models , Macaca fascicularis , Male , Minerals , Models, Animal , Risk Assessment , Soil/analysis , Soil Pollutants/analysis , Soil Pollutants/urine , Sulfides/pharmacokinetics , Sulfides/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...